News

Novo Nordisk, U.S. biotech company team up to create obesity pills
Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, ...
InvestorsHub on MSN5d
Novo Nordisk Inks $2.2 Billion Deal with Septerna to Advance Obesity and Diabetes Treatments
Novo Nordisk (NYSE: NVO) has entered into a collaboration and licensing agreement with U.S.-based biotech firm Septerna ...
Novo Nordisk and Septerna Strike $2.2 Billion Deal to Develop Obesity Pills
The deal with U.S. biotech Septerna will see the companies develop pills to treat obesity, type 2 diabetes and other ...
Novo Nordisk rode Ozempic’s success to becoming Europe’s top company. Now it’s faltering and its CEO is out.
Lars Fruergaard Jorgensen, the chief executive of once-highflying Danish drugmaker Novo Nordisk, is stepping down after eight ...
Novo Nordisk Inks $2.2 Billion Deal With Septerna To Develop Oral Weight Loss And Diabetes Drugs
Novo Nordisk and Septerna enter $2.2 billion deal to develop oral small-molecule therapies targeting obesity, diabetes, and ...
Novo Nordisk announces CEO transition as share price slips
After nearly tripling the company’s value, CEO Lars Fruergaard Jørgensen is preparing to exit amid boardroom shifts. Novo ...
Ozempic Drugmaker’s CEO Pushed Out Amid Weight-Loss Market Challenges
Lars Fruergaard Jorgensen, who has headed the pharmaceutical company for eight years, will step down after a period to ...